EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer

References

• Wen PY, MB P, Loeffler J. Metastatic Brain Cancer. Wen PY, MB P, Loeffler J (Eds). Lippincott Williams and Wilkins, PA, USA (1999).
   Google Scholar
• Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48(2), 384–394 (1981).
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Mehta MP, Patchell RA et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J. Neurooncol. 96(1), 17–32 (2010).
   PubMed Web of Science ®Google Scholar
• Alexander E 3rd, Moriarty TM, Davis RB et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J. Natl Cancer Inst. 87(1), 34–40 (1995).
   PubMed Web of Science ®Google Scholar
• Burt M, Wronski M, Arbit E, Galicich JH. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan–Kettering Cancer Center Thoracic Surgical Staff. J. Thorac. Cardiovasc. Surg. 103(3), 399–410; discussion 410 (1992).
   PubMed Web of Science ®Google Scholar
• Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494–500 (1990).
   PubMed Web of Science ®Google Scholar
• Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 109(1), 271–276 (1996).
   PubMedGoogle Scholar
• Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J. Neurosurg. 97(6), 1276–1281 (2002).
   PubMed Web of Science ®Google Scholar
• Alberola V, Camps C, Provencio M et al.; Spanish Lung Cancer Group. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group Phase III randomized trial. J. Clin. Oncol. 21(17), 3207–3213 (2003).
   PubMed Web of Science ®Google Scholar
• Bearz A, Garassino I, Tiseo M et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 68(2), 264–268 (2010).
   PubMed Web of Science ®Google Scholar
• Cortes J, Rodriguez J, Aramendia JM et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology 64(1), 28–35 (2003).
   PubMed Web of Science ®Google Scholar
• Cotto C, Berille J, Souquet PJ et al. A Phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur. J. Cancer 32A(1), 69–71 (1996).
   PubMed Web of Science ®Google Scholar
• Crinò L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized Phase III study of the Italian Lung Cancer Project. J. Clin. Oncol. 17(11), 3522–3530 (1999).
   PubMed Web of Science ®Google Scholar
• Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599–1605 (1999).
   PubMed Web of Science ®Google Scholar
• Lee DH, Han JY, Kim HT et al. Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer 113(1), 143–149 (2008).
   PubMed Web of Science ®Google Scholar
• Malacarne P, Santini A, Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 53(3), 210–213 (1996).
   PubMed Web of Science ®Google Scholar
• Minotti V, Crinò L, Meacci ML et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 20(2), 93–98 (1998).
   PubMed Web of Science ®Google Scholar
• Moscetti L, Nelli F, Felici A et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases: survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer 109(2), 274–281 (2007).
   PubMedGoogle Scholar
• Robinet G, Thomas P, Breton JL et al. Results of a Phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann. Oncol. 12(1), 59–67 (2001).
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M et al.; Italian Lung Cancer Project. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285–4291 (2002).
   PubMed Web of Science ®Google Scholar
• Bernardo G, Cuzzoni Q, Strada MR et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a Phase II study. Cancer Invest. 20(3), 293–302 (2002).
   PubMed Web of Science ®Google Scholar
• Fujita A, Ohkubo T, Hoshino H et al. Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer. Br. J. Cancer 89(6), 1008–1012 (2003).
   Google Scholar
• Lin Q, Balasubramanian K, Fan D et al. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12(9), 748–754 (2010).
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J. Clin. Oncol. 25(16), 2295–2305 (2007).
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, Verkman AS. Molecular mechanisms of brain tumor edema. Neuroscience 129(4), 1011–1020 (2004).
   PubMed Web of Science ®Google Scholar
• Lee G, Dallas S, Hong M, Bendayan R. Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations. Pharmacol. Rev. 53(4), 569–596 (2001).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J. Clin. Oncol. 21(12), 2237–2246 (2003).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16), 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009).
   PubMed Web of Science ®Google Scholar
• Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 24(16), 2549–2556 (2006).
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Kusumoto M et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1), 93–104 (2004).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Learn CA, Archer GE et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 8(11), 3496–3502 (2002).
   PubMed Web of Science ®Google Scholar
• Kitazaki T, Oka M, Nakamura Y et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49(3), 337–343 (2005).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Calandri C, Bartolini S, Crinò L. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br. J. Cancer 89(2), 246–247 (2003).
   Google Scholar
• Cappuzzo F, Ardizzoni A, Soto-Parra H et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 41(2), 227–231 (2003).
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ohrui T, Ebihara S, Yamada M, Sasaki H. Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer 43(3), 371–372 (2004).
   PubMedGoogle Scholar
• Ishida A, Kanoh K, Nishisaka T et al. Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases. Intern. Med. 43(8), 718–720 (2004).
   PubMedGoogle Scholar
• Fekrazad MH, Ravindranathan M, Jones DV Jr. Response of intracranial metastases to erlotinib therapy. J. Clin. Oncol. 25(31), 5024–5026 (2007).
   PubMedGoogle Scholar
• Namba Y, Kijima T, Yokota S et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin. Lung Cancer 6(2), 123–128 (2004).
   PubMedGoogle Scholar
• Hotta K, Kiura K, Ueoka H et al. Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 46(2), 255–261 (2004).
   PubMed Web of Science ®Google Scholar
• Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann. Oncol. 15(7), 1042–1047 (2004).
   PubMed Web of Science ®Google Scholar
• Chiu CH, Tsai CM, Chen YM, Chiang SC, Liou JL, Perng RP. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47(1), 129–138 (2005).
   PubMed Web of Science ®Google Scholar
• Wu C, Li YL, Wang ZM, Li Z, Zhang TX, Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 57(3), 359–364 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee DH, Choi Y et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65(3), 351–354 (2009).
   PubMedGoogle Scholar
• Lee DH, Han JY, Lee HG et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin. Cancer Res. 11(8), 3032–3037 (2005).
   PubMed Web of Science ®Google Scholar
• Shimato S, Mitsudomi T, Kosaka T et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol. 8(2), 137–144 (2006).
   PubMed Web of Science ®Google Scholar
• Porta R, Sánchez-Torres JM, Paz-Ares L et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur. Respir. J. 37(3), 624–631 (2011).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L Sanchez JM, Garcia-Velasco A et al. A prospective Phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. 24, 369s (2006).
   Google Scholar
• Benedetti G, Latini L, Galetta D, Colucci G, Crinò L. Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib. J. Thorac. Oncol. 4(7), 936–937 (2009).
   Google Scholar
• Grommes C, Oxnard GR, Kris MG et al. ‘Pulsatile’ high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 13(12), 1364–1369 (2011).
   PubMed Web of Science ®Google Scholar
• Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J. Neurooncol. 99(2), 283–286 (2010).
   PubMed Web of Science ®Google Scholar
• Jackman DM, Holmes AJ, Lindeman N et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J. Clin. Oncol. 24(27), 4517–4520 (2006).
   PubMed Web of Science ®Google Scholar
• Milton DT, Azzoli CG, Heelan RT et al. A Phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107(5), 1034–1041 (2006).
   PubMedGoogle Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354(6), 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou XY, Ma SL. The radiation-sensitizing effect of gefitinib on non-small-cell lung cancer A549 cell line. Chin. Clin. Oncol. 12, 814–818 (2007).
   Google Scholar
• Ma S, Xu Y, Deng Q, Yu X. Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and gefitinib in a Chinese population. Lung Cancer 65(2), 198–203 (2009).
   PubMed Web of Science ®Google Scholar
• Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, Xu Y. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis. Lung Cancer 70(2), 174–179 (2010).
   PubMed Web of Science ®Google Scholar